Showing 4501-4510 of 6000 results for "".
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- New Government Advisory Cites Risk for Ransomware Attacks on Healthcare Systemhttps://practicaldermatology.com/news/new-government-advisory-cites-risk-for-ransomware-attacks-on-healthcare-system/2460587/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Dermatologist Named AAD Patient Hero for Saving South Florida Man’s Life with Early Diagnosis of Lung Cancerhttps://practicaldermatology.com/news/dermatologist-named-aad-patient-hero-for-saving-south-florida-mans-life-with-early-diagnosis-of-lung-cancer/2460583/Brittany Smirnov, DO is an American Academy of Dermatology Patient Care Hero for her role in diagnosing and treating a patient with stage IV metastatic lung cancer. When South Florida resident Richard Danzer developed a cyst on his back that grew larger and more painful over t
- Dermatologist Named AAD Patient Hero for Providing Skin Care to People Experiencing Homelessness Amid COVID-19https://practicaldermatology.com/news/dermatologist-names-aad-patient-hero-for-providing-skin-care-to-people-experiencing-homelessness-amid-covid-19/2460582/Jennifer Tan, MD, FAAD is an American Academy of Dermatology (AAD) Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic. As the state government issued COVID-19 stay-at-home guidanc
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).